Skip to main content
. 2017 Apr 11;7:46357. doi: 10.1038/srep46357

Figure 4. Src inhibitor protects lung fibrosis in bleomycin-challenged mice.

Figure 4

(A) Mice were instilled with saline (Sal) or bleomycin (Bleo) and followed by daily treatment of PP2 (50 mg/kg, i.p. injection) or vehicle. Lung tissues at day 21 were HE stained (200×). (B) The severity of lung fibrosis was examined morphometrically and represented by Ashcroft Score. (C) Lung hydroxyproline level was measured and represented as % hydroxyproline normalized to that in vehicle-challenged mice. (D) Lung tissue lysates were Western blotted. (E) Densitometry of Src activation from Panel D. pY416 of Src levels were normalized to total Src levels. Data were represented as the fold of Src activation relative to that in the control vehicle and saline treated group. (F) Densitometry of total Src protein from Panel D. Src levels were normalized to G3PDH levels. Data were represented as the fold of Src relative to that in the control vehicle and saline treated group. Per experimental group had 8–12 mice. Data were represented as mean + SE. * represents p < 0.01.